That seems like a reasonable outcome for Acrux. Evamist sales may be below expectations, but they are still growing rapidly - and KV has a real incentive to push Evamist given its situation.
Acrux gets the rights to the other six products back, and will hopefully be able to find other partners for them. They've lost about six months of development time with them.
And Acrux keeps rights to the data needed for commercialisation of Ellavie.
Add to My Watchlist
What is My Watchlist?
